Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic Immunotherapy for Grass Pollen Allergy
NCT05191186Phase 3Completed
- Sponsor
- Aarhus University Hospital
- Start
- Feb 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of alutard phleum pratense in allergic rhinoconjunctivitis (ARC) and allergic asthma (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Combined symptom and medication score at 2 years. Started Feb 2020; status: completed.
02
Drugs
alutard phleum pratense
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT05191186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191186.